Objective:To explore the therapeutic effect and safety of dexamethasone combined with ulinastatin in pa-tients with acute severe viral myocarditis(ASVMC).Methods:Clinical data of 92 ASVMC patients treated in our hospital from August 2018 to November 2020 were retrospectively collected,and divided into dexamethasone group(n=46)and combined treatment group(n=46,dexamethasone combined with ulinastatin)according to different treatment program.Each group received corresponding medication based on routine therapy for four weeks.Thera-peutic effect,levels of myocardial enzyme spectrum indexes[cardiac troponin Ⅰ(cTnⅠ),creatine kinase isoenzyme MB(CK-MB),lactate dehydrogenase(LDH)]and related indexes of cardiomyocyte apoptosis[soluble factor-related apoptosis(sFas),soluble factor-related apoptosis ligand(sFasL)]before and after treatment,and inci-dence of adverse reactions were compared between two groups.Results:The total effective rate(91.30％vs.73.91％)of combined treatment group was significantly higher than that of dexamethasone group(P=0.028).Compared with dexamethasone group,there were significant reductions in serum levels of cTnⅠ[(4.38±1.02)ng/ml vs.(1.76±0.24)ng/ml],CK-MB[(29.85±5.30)U/L vs.(20.26±4.18)U/L],LDH[(202.84±16.70)U/L vs.(184.21±12.63)U/L],sFas[(2.82±0.37)ng/L vs.(2.39±0.24)ng/L]and sFasL[(0.16±0.04)ng/L vs.(0.08±0.02)ng/L]in combined treatment group after 4-week treatment(P＜0.001 all).There was no sig-nificant difference in incidence rate of adverse reactions during treatment between two groups(P=0.711).Conclusion:Ulinastatin combined with dexamethasone can further inhibit myocardial cell apoptosis,and promote the improvement of myocardial function with significant therapeutic effect in patients with acute severe viral myocarditis and it's safe.
维普
万方数据